Corporate | 3 March 2016 09:00


Evonik Industries AG: Evonik acquires Norwegian manufacturer of food ingredients (news with additional features)

DGAP-News: Evonik Industries AG / Key word(s): Takeover

2016-03-03 / 09:00
The issuer is solely responsible for the content of this announcement.

Embargoed until: March 3, 2016, 7 a.m.

Evonik acquires Norwegian manufacturer of food ingredients

Evonik Industries acquires the company MedPalett AS, with headquarters in Sandnes (Norway), on March 3, 2016. MedPalett AS specializes in food ingredients containing anthocyanins. The acquisition helps Evonik expand the portfolio of its Health Care Business Line in the area of advanced food ingredients. The parties have agreed not to disclose the purchase price.

Anthocyanins are known for their natural antioxidant properties. Numerous international studies suggest broad health-promoting properties including the prevention of cardiovascular disease.

“We are seeing an increase in demand for innovative food ingredients, especially those made from natural substances with scientifically proven benefits, and that’s something we want to be a part of,” says Dr. Reiner Beste, chairman of the Board of Management of Evonik Nutrition & Care GmbH.

MedPalett, which previously belonged to the Norwegian Biolink Group, developed a berry extract from wild Scandinavian
bilberries and black currants from New Zealand that has a particularly high and stable anthocyanin content. The company manufactures the ingredient itself. The berry extract, which is marketed as a dietary supplement under the brand name Medox(R), has been available in Scandinavia since the year 2000.

Evonik has distributed the berry extract since 2015 under the name Healthberry(TM) 865, with exclusive distribution rights in Canada, Brazil, China, Japan, Korea, Australia, New Zealand, and South Africa.

“We have been a partner to the food ingredients industry for decades with our high-purity amino acids. Expanding our portfolio with nutritional solutions which promote health is a logical step in the development of our Health Care business,” says Dr. Jean-Luc Herbeaux, head of the Health Care Business Line at Evonik. For MedPalett, the integration into the Evonik Group primarily means improved access to international markets and higher R&D resources.

Company information
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion.

About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around
EUR4.9 billion in 2015.

Disclaimer
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.




Contact:
Tim Lange
Head of Investor Relations
Phone +49 201 177-3150
tim.lange@evonik.com
Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.com

Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Dr. Ralph Sven Kaufmann
Christian Kullmann
Thomas Wessel
Ute Wolf

Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003


+++++
Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=VLHEPYKNEM
Document title: IR News MedPalett

2016-03-03 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: investor-relations@evonik.com
Internet: www.evonik.com
ISIN: DE000EVNK013, XS0911405784
WKN: EVNK01, A1TM7T
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX; Luxemburg
End of News DGAP News Service

show this